# US 2022/0023344 A1 · Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023344 A1
- Document ID: US20220023344A1
- Status: Published application
- Kind: A1
- Application number: 17/359,041
- Filed: 2021-06-25
- Published: 2022-01-27
- Earliest claimed: 2020-06-26
- Applicants: CRISPR Therapeutics AG
- Inventors: Jonathan Alexander TERRETT; Demetrios KALAITZIDIS; Ewelina MORAWA; Mark BENTON
- Web page: https://patentgrep.com/patent/US20220023344A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 35/00: Antineoplastic agents
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/03: containing a transmembrane segment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for treating a B cell malignancy comprising a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and optionally an NK cell inhibitor (e.g., daratumumab). The genetically engineered immune cells may comprise a disrupted TRAC gene, a disrupted β2M gene, or both.

## Claims

### Claim 1

A method for treating a B-cell malignancy in a human patient, the method comprising:
(i) administering to a human patient having a first dose of B-cell malignancy a natural killer (NK) cell inhibitor; and
(ii) administering to the human patient a first dose of a population of genetically engineered T cells after step (ii), wherein the population of genetically engineered T cells comprising T cells that comprise (a) a nucleic acid coding for a chimeric antigen receptor (CAR) that binds CD19;
optionally wherein the genetically engineered T cells are deficient in expression of MHC Class-I.

### Claim 2 (depends on 1)

The method of claim 1, the CAR comprises an anti-CD19 single chain variable fragment (scFv) that comprises the same heavy chain complementary determining regions (CDRs) as those in a heavy chain variable region set forth in SEQ ID NO: 51, and the same light chain CDRs as those in a light chain variable region set forth in SEQ ID NO: 52.

### Claim 3 (depends on 1)

The method of claim 1, wherein the population of genetically engineered T cells comprise T cells that comprise (b) a disrupted beta 2-microglobulin (β2M) gene.

### Claim 4 (depends on 3)

The method of claim 3, wherein the population of genetically engineered T cells comprising T cells that comprise (c) a disrupted T cell receptor alpha constant (TRAC) gene.

### Claim 4 (depends on 1)

The method of claim 1, further comprising, between step (i) and step (ii), (iii) subjecting the human patient to a lymphodepletion treatment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first dose of the population of genetically engineered T cells is administered to the human patient at a dose of about 1×107 to about 1×109 CAR+ T cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the first dose of the population of genetically engineered T cells is about 3×107, about 1×108, about 3×108, about 4.5×108, about 6×108, or about 9×108 CAR+ T cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the population of genetically engineered T cells administered to the human patient per dose contains no more than 7×104 TCR+ T cells/kg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the NK cell inhibitor comprises an anti-CD38 antibody.

### Claim 9 (depends on 8)

The method of claim 8, wherein the anti-CD38 antibody is daratumumab.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first dose of daratumumab is about 16 mg/kg via intravenous infusion.

### Claim 11 (depends on 10)

The method of claim 10, wherein the first dose of daratumumab is about 16 mg/kg via intravenous infusion, which is administered to the human patient at 8 mg/kg per day for two consecutive days.

### Claim 12 (depends on 9)

The method of claim 9, wherein the first dose of daratumumab is about 1800 mg via subcutaneous injection.

### Claim 13 (depends on 4)

The method of claim 4, wherein the first dose of NK cell inhibitor is administered to the human patient at least one day prior to the lymphodepletion treatment.

### Claim 14 (depends on 4)

The method of claim 4, wherein the first dose of the population of genetically engineered T cells is administered to the human patient within 10 days after the first dose of the NK cell inhibitor.

### Claim 15 (depends on 1)

The method of claim 1, further comprising (iv) administering to the human patient at least one subsequent dose of the NK cell inhibitor after step (ii).

### Claim 16 (depends on 15)

The method of claim 15, wherein step (iv) comprises administering to the human patient a second dose of the NK inhibitor 24 to 32 days after the first dose of the population of the genetically engineered T cells, and optionally a third dose of the NK inhibitor 56 to 64 days after the first dose of the population of genetically engineered T cells, when the human patient shows stable disease (SD) or better at least 4 weeks after the first dose of the population of genetically engineered T cells.

### Claim 17 (depends on 16)

The method of claim 16, wherein the NK inhibitor is daratumumab and wherein the second dose thereof is 16 mg/kg by intravenous infusion or 1800 mg by subcutaneous injection, and/or the third dose thereof is 16 mg/kg by intravenous infusion or 1800 mg by subcutaneous injection.

### Claim 18 (depends on 4)

The method of claim claim 4, wherein the lymphodepletion treatment in step (iii) comprises co-administration to the human patient fludarabine at about 30 mg/m2 and cyclophosphamide at about 500 mg/m2 per day for three days.

### Claim 19 (depends on 4)

The method of claim 4, wherein prior to step (iii), the human patient does not show one or more of the following features:
(a) significant worsening of clinical status,
(b) requirement for supplemental oxygen to maintain a saturation level of greater than 91%,
(c) uncontrolled cardiac arrhythmia,
(d) hypotension requiring vasopressor support,
(e) active infection,
(f) grade ≥2 acute neurological toxicity, and
(g) unresolved infusion reaction due to the NK cell inhibitor.

### Claim 20 (depends on 4)

The method of claim 4, wherein step (iii) is performed about 2-7 days prior to step (ii).

### Claim 21 (depends on 4)

The method of claim 4, wherein after step (iii) and prior to step (ii), the human patient does not show one or more of the following features:
(a) active uncontrolled infection;
(b) worsening of clinical status compared to the clinical status prior to step (iii); and
(c) grade ≥2 acute neurological toxicity.

### Claim 22 (depends on 1)

The method of claim 1, further comprising (v) monitoring the human patient for development of acute toxicity after step (ii); and (vi) managing the acute toxicity if the acute toxicity occurs.

### Claim 23 (depends on 22)

The method of claim 22, wherein step (v) is performed for at least 28 days after administration of the population of genetically engineered T cells.

### Claim 24 (depends on 22)

The method of claim 22, wherein the acute toxicity comprises tumor lysis syndrome (TLS), cytokine release syndrome (CRS), immune effector cellassociated neurotoxicity syndrome (ICANS), B cell aplasia, hemophagocytic lymphohistiocytosis (HLH), cytopenia, graft-versus-host disease (GvHD), hypertension, viral encephalitis, renal insufficiency, or a combination thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein the B cell malignancy is non-Hodgkin lymphoma, which optionally is selected from the group consisting of diffuse large B cell lymphoma (DLBCL), high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, transformed follicular lymphoma (FL), and grade 3b FL.

### Claim 26 (depends on 25)

The method of claim 25, wherein DLBCL is DLBCL not otherwise specified (NOS).

### Claim 27 (depends on 25)

The method of claim 25, wherein the human patient has at least one measurable lesion that is fluorodeoxyglucose positron emission tomography (PET)-positive.

### Claim 28 (depends on 25)

The method of claim 25, wherein the B cell malignancy is refractory and/or relapsed.

### Claim 29 (depends on 25)

The method of claim 25, wherein the human patient has undergone one or more lines of prior anti-cancer therapies.

### Claim 30 (depends on 29)

The method of claim 29, wherein the human patient has undergone two or more lines of prior anti-cancer therapies.

### Claim 31 (depends on 29, 30)

The method of claim 29 or claim 30, wherein the prior anti-cancer therapies comprise an anti-CD20 antibody, an anthracycline-containing regimen, or a combination thereof.

### Claim 32 (depends on 29)

The method of claim 29, wherein the human patient has refractory or relapsed transformed FL and has undergone at least one line of chemotherapy for disease after transformation to DLBCL.

### Claim 33 (depends on 28)

The method of claim 28, wherein the B cell malignancy is refractory, and the human patient has progressive disease on last therapy, or has stable disease following at least two cycles of therapy with duration of stable disease of up to 6 months.

### Claim 34 (depends on 25)

The method of claim 25, wherein the human patient has failed prior autologous hematopoietic stem cell transplantation (HSCT) or ineligible for prior autologous HSCT.

### Claim 35 (depends on 25)

The method of claim 25, wherein the human patient is subject to an additional anti-cancer therapy after treatment with the population of genetically engineered T cells.

### Claim 36 (depends on 25)

The method of claim 25, wherein the human patient has one or more of the following features:
(a) has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
(b) adequate renal, liver, cardiac, and/or pulmonary function;
(c) free of prior gene therapy or modified cell therapy;
(d) free of prior treatment comprising an anti-CD19 antibody;
(e) free of prior allogeneic HSCT;
(f) free of detectable malignant cells from cerebrospinal fluid;
(g) free of brain metastases;
(h) free of prior central nervous system disorders;
(i) free of unstable angina, arrhythmia, and/or myocardial infarction;
(j) free of uncontrolled infection;
(k) free of immunodeficiency disorders or autoimmune disorders that require immunosuppressive therapy; and
(l) free of infection by human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.

### Claim 37 (depends on 25)

The method of claim 25, wherein the human patient is not diagnosed for Burkitt's lymphoma or leukemia.

### Claim 38 (depends on 25)

The method of claim 25, further comprising administering to the human patient at least one subsequent dose of the population of genetically engineered T cells.

### Claim 39 (depends on 25)

The method of claim 25, wherein the first dose of the population of genetically engineered T cells is at least 3×108 CAR+ T cells.

### Claim 40 (depends on 38)

The method of claim 38, wherein the human patient receives a second dose of the population of genetically engineered T cells about 4-8 weeks after the first dose of the population of genetically engineered T cells.

### Claim 41 (depends on 40)

The method of claim 40, wherein the human patient achieves stable disease (SD), particle response (PR), or complete response (CR) at least 4 weeks after the first dose.

### Claim 42 (depends on 38)

The method of claim 38, wherein the human patient receives a subsequent lymphodepletion treatment about 2-7 days prior to each of the subsequent dose of the population of the genetically engineered T cells.

### Claim 43 (depends on 38)

The method of claim 38, wherein the human patient experiences significant cytopenias after steps (i)-(iii), and wherein the human patient does not receive subsequent lymphodepletion treatment prior to each of the subsequent dose of the population of the genetically engineered T cells.

### Claim 44 (depends on 25)

The method of claim 25, wherein the first dose of the population of genetically engineered T cells is at least 4.5×108 CAR+ T cells or at least 6×108 CAR+ T cells.

### Claim 45 (depends on 38)

The method of claim 38, wherein the human patient receives a second dose of the population of genetically engineered T cells about 7-9 days after the first dose of the population of genetically engineered T cells; and wherein the human patient does not receive a subsequent lymphodepletion treatment prior to the second dose of the population of genetically engineered T cells.

### Claim 46 (depends on 45)

The method of claim 45, wherein the human patient receives a third dose of the population of genetically engineered T cells about 4-8 weeks after the first dose of the population of genetically engineered T cells.

### Claim 47 (depends on 46)

The method of claim 46, wherein the human patient achieves stable disease (SD), particle response (PR), or complete response (CR) at least 4 weeks after the first dose.

### Claim 48 (depends on 46)

The method of claim 46, wherein the human patient receives a subsequent lymphodepletion treatment about 2-7 days prior to the third dose of the population of the genetically engineered T cells.

### Claim 49 (depends on 46)

The method of claim 46, wherein the human patient experiences significant cytopenias after steps (i)-(iii), and wherein the human patient does not receive subsequent lymphodepletion treatment prior to the third dose of the population of the genetically engineered T cells.

### Claim 50 (depends on 38)

The method of claim 38 wherein the human patient does not receive subsequent doses of the NK inhibitor.

### Claim 51 (depends on 38)

The method of claim 38, wherein the subsequent dose(s) is about 3×107, about 1×108, about 3×108, about 4.5×108, about 6×108, or about 9×108 CAR+ T cells.

### Claim 52 (depends on 1)

The method of claim 1, wherein the human patient has B-cell acute lymphoblastic leukemia (ALL).

### Claim 53 (depends on 52)

The method of claim 52, wherein the human patient has refractory and/or relapsed B cell ALL.

### Claim 54 (depends on 52)

The method of claim 52, wherein the human patient
(a) has undergone two or more lines of prior anti-cancer therapies;
(b) has bone marrow relapse after allogeneic hematopoietic stem cell transplantation (HSCT);
(c) is Philadelphia chromosome-positive (Ph+), and is intolerant to or ineligible for tyrosine kinase inhibitor (TKI) therapy, or has progressed after at least 1 line of TKI therapy;
(d) has bone marrow involvement with <50% blasts; and/or
(e) is bone marrow minimal residue disease (MRD) positive with <5% blasts.

### Claim 55 (depends on 52)

The method of claim 52, wherein the human patient has one or more of the following features:
(a) has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
(b) adequate renal, liver, cardiac, and/or pulmonary function;
(c) free of prior gene therapy or modified cell therapy;
(d) free of prior treatment comprising an anti-CD19 antibody;
(e) free of prior allogeneic HSCT;
(f) free of detectable malignant cells from cerebrospinal fluid;
(g) free of brain metastases;
(h) free of prior central nervous system disorders;
(i) free of unstable angina, arrhythmia, and/or myocardial infarction;
(j) free of uncontrolled infection;
(k) free of immunodeficiency disorders or autoimmune disorders that require immunosuppressive therapy;
(l) free of infection by human immunodeficiency virus, hepatitis B virus, or hepatitis C virus; and
(m) free of extramedullary disease.

### Claim 56 (depends on 52)

The method of claim 52, further comprising administering to the human patient at least one subsequent dose of the population of genetically engineered T cells.

### Claim 57 (depends on 52)

The method of claim 52, wherein the first dose of the population of genetically engineered T cells is at least 3×107 CAR+ T cells, 1×108 CAR+ T cells or at least 3×108 CAR+ T cells.

### Claim 58 (depends on 56)

The method of claim 56, wherein the human patient has a decrease in bone marrow blast count of at least 50% about 4 weeks after the first dose of the population of genetically engineered T cells.

### Claim 59 (depends on 56)

The method of claim 56, wherein the human patient receives a second dose of the population of genetically engineered T cells about 4 to 8 weeks after the first dose of the population of genetically engineered T cells; optionally wherein the second dose is administered to the subject about 4 weeks after the first dose.

### Claim 60 (depends on 59)

The method of claim 59, wherein the human patient is in a morphologic remission and is MRD-remains positive.

### Claim 61 (depends on 56)

The method of claim 56, wherein the human patient shows progressive disease (PD) and had prior response.

### Claim 62 (depends on 56)

The method of claim 56, wherein the human patient receives a subsequent lymphodepletion treatment about 2-7 days prior to each of the subsequent dose of the population of the genetically engineered T cells.

### Claim 63 (depends on 56)

The method of claim 56, wherein the human patient experiences significant cytopenias after steps (i)-(iii), and wherein the human patient does not receive subsequent lymphodepletion treatment prior to each of the subsequent dose of the population of the genetically engineered T cells.

### Claim 64 (depends on 56)

The method of claim 56, wherein the subsequent dose(s) is about 3×107, about 1×108, about 3×108, about 4.5×108, about 6×108, or about 9×108 CAR+ T cells.

### Claim 65 (depends on 1)

The method of claim 1, wherein the CAR comprises an anti-CD19 single chain variable fragment (scFv) that comprises a heavy chain variable region set forth in SEQ ID NO: 51, and a light chain variable region set forth in SEQ ID NO: 52.

### Claim 66 (depends on 65)

The method of claim 65, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO: 47.

### Claim 67 (depends on 66)

The method of claim 66, wherein the CAR that binds CD19 comprises the amino acid sequence of SEQ ID NO: 40.

### Claim 68 (depends on 3)

The method of claim 3, wherein the nucleic acid encoding the CAR is inserted in the disrupted TRAC gene.

### Claim 69 (depends on 3)

The method of claim 3, wherein the disrupted TRAC gene comprises a deletion of a fragment comprising the nucleotide sequence of SEQ ID NO: 26.

### Claim 70 (depends on 69)

The method of claim 69, wherein the nucleic acid encoding the anti-CD19 CAR is inserted at the site of the deletion in the disrupted TRAC gene.

### Claim 71 (depends on 70)

The method of claim 70, wherein the disrupted TRAC gene comprises the nucleotide sequence of SEQ ID NO: 54.

### Claim 72 (depends on 3)

The method of claim 3, wherein the disrupted β2M gene in the population of genetically engineered T cells comprises at least one of the nucleotide sequence set forth in SEQ ID NOs: 9-14.

### Claim 73 (depends on 1)

The method of claim 1, wherein the population of the genetically engineered T cells is allogeneic to the human patient.

### Claim 74 (depends on 1)

The method of claim 1, wherein at least 90% of the T cells in the population of genetically engineered T cells do not express a detectable level of TCR surface protein.

### Claim 75 (depends on 1)

The method of claim 1, wherein at least 70% of the T cells in the population of genetically engineered T cells do not express a detectable level of TCR surface protein; wherein at least 50% of the T cells in the population of genetically engineered T cells do not express a detectable level of B2M surface protein; and/or wherein at least 30% of the T cells in the population of genetically engineered T cells express a detectable level of the CAR.

### Claim 76 (depends on 75)

The method of claim 75, wherein at least 99.5% of the T cells in the population of genetically engineered T cells do not express a detectable level of TCR surface protein.

### Claim 77 (depends on 1)

The method of claim 1, wherein at least 70% of the T cells in the population of genetically engineered T cells do not express a detectable level of B2M surface protein.

### Claim 78 (depends on 77)

The method of claim 77, wherein at least 85% of the T cells in the population of the genetically engineered T cells do not express a detectable level of B2M surface protein.

### Claim 79 (depends on 1)

The method of claim 1, wherein at least 50% of the T cells in the population of genetically engineered T cells express a detectable level of the CAR.

### Claim 80 (depends on 79)

The method of claim 79, wherein at least 70% of the T cells in the population of genetically engineered T cells express a detectable level of the CAR.

### Claim 81 (depends on 1)

The method of claim 1, wherein the population of genetically engineered T cells are administered to the human patient via intravenous infusion.

### Claim 82 (depends on 1)

The method of claim 1, wherein the population of genetically engineered T cells are suspended in a cryopreservation solution.

### Claim 83

A method for treating acute lymphoblastic leukemia (ALL) in a human patient, the method comprising:
(i) subjecting a human patient having ALL to a lymphodepletion treatment; and
(ii) administering to the human patient a first dose of a population of genetically engineered T cells after step (i),
wherein the population of genetically engineered T cells comprising T cells comprise (a) a nucleic acid coding for a chimeric antigen receptor (CAR) that binds CD19; and
wherein the first dose of the population of genetically engineered T cells is administered to the human patient at a dose of about 1×107 to about 1×109 CAR+ T cells.

### Claim 84 (depends on 83)

The method of claim 83, wherein the CAR comprises an anti-CD19 single chain variable fragment (scFv) that comprises the same heavy chain complementary determining regions (CDRs) as those in a heavy chain variable region set forth in SEQ ID NO: 51, and the same light chain CDRs as those in a light chain variable region set forth in SEQ ID NO: 52.

### Claim 85 (depends on 83)

The method of claim 83, wherein the population of genetically engineered T cells comprising T cells that comprise (b) a disrupted T cell receptor alpha constant (TRAC) gene, and/or (c) a disrupted beta 2-microglobulin (β2M) gene.

### Claim 86 (depends on 85)

The method of claim 85, wherein the population of genetically engineered T cells comprising T cells that comprise (b) a disrupted T cell receptor alpha constant (TRAC) gene, and (c) a disrupted beta 2-microglobulin (β2M) gene.

### Claim 87 (depends on 83)

The method of claim 83, wherein the first dose of the population of genetically engineered T cells is about 3×107, about 1×108, about 3×108, about 4.5×108, about 6×108, or about 9×108 CAR+ T cells.

### Claim 88 (depends on 83)

The method of claim 83, wherein the first dose of the population of the genetically engineered T cells is at least 1×108 or at least about 3×108 CAR+ T cells.

### Claim 89 (depends on 83)

The method of claim 83, wherein the population of genetically engineered T cells administered to the human patient per dose contains no more than 7×104 TCR+ T cells/kg.

### Claim 90 (depends on 83)

The method of claim claim 83, wherein the lymphodepletion treatment in step (i) comprises co-administration to the human patient fludarabine at about 30 mg/m2 and cyclophosphamide at about 500 mg/m2 per day for three days.

### Claim 91 (depends on 83)

The method of claim 83, wherein prior to step (i), the human patient does not show one or more of the following features:
(a) significant worsening of clinical status,
(b) requirement for supplemental oxygen to maintain a saturation level of greater than 91%,
(c) uncontrolled cardiac arrhythmia,
(d) hypotension requiring vasopressor support,
(e) active infection, and
(f) grade ≥2 acute neurological toxicity.

### Claim 92 (depends on 83)

The method of claim 83, wherein step (i) is performed about 2-7 days prior to step (ii).

### Claim 93 (depends on 83)

The method of claim 83, wherein after step (i) and prior to step (ii), the human patient does not show one or more of the following features:
(a) active uncontrolled infection;
(b) worsening of clinical status compared to the clinical status prior to step (i); and
(c) grade ≥2 acute neurological toxicity.

### Claim 94 (depends on 83)

The method of claim 83, further comprising (iii) monitoring the human patient for development of acute toxicity after step (ii); and (iv) managing the acute toxicity if occurs.

### Claim 95 (depends on 94)

The method of claim 94, wherein step (iii) is performed for at least 28 days after the first dose of the population of genetically engineered T cells.

### Claim 96 (depends on 94)

The method of claim 94, wherein the acute toxicity comprises tumor lysis syndrome (TLS), cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), B cell aplasia, hemophagocytic lymphohistiocytosis (HLH), cytopenia, graft-versus-host disease (GvHD), hypertension, renal insufficiency, viral encephalitis, or a combination thereof.

### Claim 97 (depends on 83)

The method of claim 83, wherein the human patient has B-cell ALL.

### Claim 98 (depends on 97)

The method of claim 97, wherein the human patient has refractory and/or relapsed B cell ALL.

### Claim 99 (depends on 98)

The method of claim 98, wherein the human patient:
(a) has undergone two or more lines of prior anti-cancer therapies;
(b) has bone marrow relapse after allogeneic hematopoietic stem cell transplantation (HSCT);
(c) is Philadelphia chromosome-positive (Ph+), and is intolerant to or ineligible for tyrosine kinase inhibitor (TKI) therapy, or has progressed after at least 1 line of TKI therapy;
(d) has bone marrow involvement with <50% blasts; and/or
(e) is bone marrow minimal residue disease (MRD) positive with <5% blasts.

### Claim 100 (depends on 99)

The method of claim 99, wherein the prior anti-cancer therapies comprise a chemotherapy, an allogeneic stem cell transplantation, or a combination thereof; optionally wherein the chemotherapy comprises vincristine, corticosteroids, an anthracycline-containing regimen, or a combination thereof.

### Claim 101 (depends on 83)

The method of claim 83, wherein the human patient is subject to an additional anti-cancer therapy after treatment with the population of genetically engineered T cells.

### Claim 102 (depends on 83)

The method of claim 83, wherein the human patient has one or more of the following features:
(a) has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
(b) adequate renal, liver, cardiac, and/or pulmonary function;
(c) free of prior gene therapy or modified cell therapy;
(d) free of prior treatment comprising an anti-CD19 antibody;
(e) free of prior allogeneic HSCT;
(f) free of detectable malignant cells from cerebrospinal fluid;
(g) free of brain metastases;
(h) free of prior central nervous system disorders;
(i) free of unstable angina, arrhythmia, and/or myocardial infarction;
(j) free of uncontrolled infection;
(k) free of immunodeficiency disorders or autoimmune disorders that require immunosuppressive therapy;
(l) free of infection by human immunodeficiency virus, hepatitis B virus, or hepatitis C virus;
(m) free of Burkitt's lymphoma or leukemia; and
(n) free of isolated extramedullary disease.

### Claim 103 (depends on 83)

The method of claim 83, further comprising (iii) administering to the human patient at least one subsequent dose of the population of genetically engineered T cells.

### Claim 104 (depends on 103)

The method of claim 103, wherein the human patient has a decrease in bone marrow blast count of at least 50% about 4 weeks after the first dose of the population of genetically engineered T cells.

### Claim 105 (depends on 103)

The method of claim 103, wherein the human patient receives a second dose of the population of genetically engineered T cells about 4 to 8 weeks after the first dose of the population of genetically engineered T cells.

### Claim 106 (depends on 105)

The method of claim 105, wherein the human patient is in a morphologic remission and is MRD-remains positive.

### Claim 107 (depends on 103)

The method of claim 103, wherein the human patient shows progressive disease (PD) and had prior response.

### Claim 108 (depends on 103)

The method of claim 103, wherein the human patient receives a subsequent lymphodepletion treatment about 2-7 days prior to each of the subsequent dose of the population of the genetically engineered T cells.

### Claim 109 (depends on 103)

The method of claim 103, wherein the human patient experiences significant cytopenias after steps (i)-(iii), and wherein the human patient does not receive subsequent lymphodepletion treatment prior to each of the subsequent dose of the population of the genetically engineered T cells.

### Claim 110 (depends on 103)

The method of claim 103, wherein the subsequent dose(s) is about 3×107, about 1×108, about 3×108, about 4.5×108, about 6×108, or about 9×108 CAR+ T cells.

### Claim 111 (depends on 83)

The method of claim 83, wherein the CAR comprises an anti-CD19 single chain variable fragment (scFv) that comprises a heavy chain variable region set forth in SEQ ID NO: 51, and a light chain variable region set forth in SEQ ID NO: 52.

### Claim 112 (depends on 111)

The method of claim 111, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO: 47.

### Claim 113 (depends on 112)

The method of claim 112, wherein the CAR that binds CD19 comprises the amino acid sequence of SEQ ID NO: 40.

### Claim 114 (depends on 86)

The method of claim 86, wherein the disrupted TRAC gene comprises a deletion of a fragment comprising the nucleotide sequence of SEQ ID NO: 26.

### Claim 115 (depends on 114)

The method of claim 114, wherein the nucleic acid encoding the anti-CD19 CAR is inserted at the site of the deletion in the disrupted TRAC gene.

### Claim 116 (depends on 115)

The method of claim 115, wherein the disrupted TRAC gene comprises the nucleotide sequence of SEQ ID NO: 54.

### Claim 117 (depends on 86)

The method of claim 86, wherein the disrupted 62M gene in the population of genetically engineered T cells comprises at least one of the nucleotide sequence set forth in SEQ ID NOs: 9-14.

### Claim 118 (depends on 83)

The method of claim 83, wherein the population of genetically engineered T cells is allogeneic to the human patient.

### Claim 119 (depends on 83)

The method of claim 83, wherein at least 90% of the T cells in the population of genetically engineered T cells do not express a detectable level of TCR surface protein.

### Claim 120 (depends on 83)

The method of claim 83, wherein at least 70% of the T cells in the population of genetically engineered T cells do not express a detectable level of TCR surface protein, wherein at least 50% of the T cells in the population of genetically engineered T cells do not express a detectable level of B2M surface protein; and/or wherein at least 30% of the T cells in the population of genetically engineered T cells express a detectable level of the CAR.

### Claim 121 (depends on 120)

The method of claim 120, wherein at least 99.5% of the T cells in the population of genetically engineered T cells do not express a detectable level of TCR surface protein.

### Claim 122 (depends on 83)

The method of claim 83, wherein at least 70% of the T cells in the population of genetically engineered T cells do not express a detectable level of B2M surface protein.

### Claim 123 (depends on 122)

The method of claim 122, wherein at least 85% of the T cells in the population of the genetically engineered T cells do not express a detectable level of B2M surface protein.

### Claim 124 (depends on 83)

The method of claim 83, wherein at least 50% of the T cells in the population of genetically engineered T cells express a detectable level of the CAR.

### Claim 125 (depends on 124)

The method of claim 124, wherein at least 70% of the T cells in the population of genetically engineered T cells express a detectable level of the CAR.

### Claim 126 (depends on 83)

The method of claim 83, wherein the population of genetically engineered T cells are administered to the human patient via intravenous infusion.

### Claim 127 (depends on 83)

The method of claim 83, wherein the population of genetically engineered T cells are suspended in a cryopreservation solution.
